Journal
Information Content Entity
Continuant
Entity
Periodical
Generically Dependent Continuant
Collection
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease
Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study
Treatment for hepatitis C virus with pegylated interferon-¿ plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model
Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences
Factors associated with the number of drugs in darunavir/cobicistat regimens
Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral and low-grade systemic inflammation
Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial.
Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study
Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain
Criteria of time and antibiotic susceptibility in the elimination of duplicates when calculating resístance frequencies. Journal of Antimicrobial Chemotherapy 2003; 52: 132-134.
Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.
Effectiveness and safety of an abacavir/lamivudine+rilpivirine regimen for the treatment of HIV-1 infection in naive patients
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1infection in clinical practice
Factors associated with the number of drugs in darunavir/cobicistat regimens.
Drug resistance mutations in patients infected with HIV-2 living in Spain.
Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.
Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score¿adjusted retrospective cohort study
Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion
. Integrase inhibitors in children and adolescents: clinical use and resistance.
Integrase inhibitors in children and adolescents: clinical use and resistance
Genetic environment and location of the lnu(A) and lnu(B)
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Long-term effects of an intensive intervention in HIV-infected patients with moderate-high atherosclerotic cardiovascular risk
Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A
Dosing regimen of meropenem for adults with severe burns: a population PK study with Monte Carlo simulations
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation
Effect of Replacing Glutamic Residues upon the Biological Activity and Stability of the circular Enterocin AS-48.
HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.
Resistance to empirical ß-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study
The future of antiretroviral therapy: challenges and needs
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial
A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk
Uptake of the antileishmania drug tafenoquine follows a sterol-dependent diffusion process in Leishmania.
Fluoroquinolone resistance in Escherichia coli and Klebsiella pneumoniae over 18 years: effect of different systems for eliminating duplicates
Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316)
Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance
Simplification to dual therapy (atazanavir/ritonavir¿+¿lamivudine) versus standard triple therapy [atazanavir/ritonavir¿+¿two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial
Physicians opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
Pharmacokinetic studies of linezolid and teicoplanin in the critically ill
Redefining therapeutic success in HIV patients: an expert view
Dual therapy (atazanavir/ritonavir¿+¿lamivudine) versus standard triple therapy [atazanavir/ritonavir¿+¿two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine
No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotypingensitive HIV-1 genotyping
RDF description of JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY - http://research.umh.es/vivo/pub/revista/0305-7453